Physician profile
John Van Wagoner
NPI 1053389502
$5,060.09
in general payments reported to CMS, 2019-2025
33 companies · $2,767 in 2025
The $2,767 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $682 · 2020: $217 · 2021: $390 · 2022: $497 · 2023: $160 · 2024: $348 · 2025: $2,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,073 · Education: $135 · Consulting Fee: $65.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,073.37 |
| Education | $135.22 |
| Consulting Fee | $65.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,055.26 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $475.90 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $395.72 | 2019-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $379.33 | 2020-2025 | Cuvitru, Eohilia, Takhzyro |
| Novartis Pharmaceuticals Corporation | $327.49 | 2021-2025 | |
| Genzyme Corporation | $256.77 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $242.42 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $213.49 | 2025 | Nemluvio |
| Octapharma USA, INC. | $190.82 | 2019-2021 | |
| Amgen INC. | $168.03 | 2022-2025 | Tezspire |
| Lilly USA, LLC | $161.63 | 2024-2025 | Ebglyss, Taltz |
| Grifols USA, LLC | $154.57 | 2019-2025 | Xembify, Gamunex-C |
| Alk-Abello, INC | $96.08 | 2019-2021 | |
| Kaleo, INC. | $85.06 | 2019-2023 | Auvi-Q |
| Organon LLC | $82.45 | 2025 | Vtama |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $79.19 | 2023-2025 | Ruconest |
| Pfizer INC. | $71.75 | 2021-2025 | |
| Adma Biomanufacturing LLC | $65.59 | 2025 | |
| Optinose US, INC. | $64.80 | 2019-2025 | |
| Incyte Corporation | $63.51 | 2022-2025 | Opzelura, Opzelura |
| Sanofi-Aventis U.S. LLC | $54.95 | 2023 | |
| Leo Pharma INC. | $53.74 | 2022 | |
| Kedrion Biopharma, INC. | $42.68 | 2025 | Gammaked, Kedrab, Koate |
| Teva Pharmaceuticals USA, INC. | $41.00 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $38.59 | 2025 | Zoryve |
| Azurity Pharmaceuticals, INC. | $34.03 | 2025 | Alvesco |
| Shire North American Group INC | $33.70 | 2019 | |
| Genentech USA, INC. | $32.48 | 2019 | |
| Blueprint Medicines Corporation | $26.65 | 2025 | Ayvakit |
| Csl Behring | $23.23 | 2024 | Hizentra, Privigen |
| Gc Biopharma USA, INC. | $21.83 | 2025 | Alyglo |
| Hikma Pharmaceuticals USA | $15.67 | 2025 | Ryaltris |
| Almirall LLC | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Van Wagoner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.